Email Facebook Twitter

EXCLUSIVE: Robin Young, CEO, Amur Minerals #AMC talks long-term strategy

Finance & Stock Market News

UPDATE 1-FDA OKs AstraZeneca's influenza vaccine

Wed, 29th Feb 2012 23:46

Feb 29 (Reuters) - U.S. health regulators approved AstraZeneca's vaccine t
o prevent seasonal influenza in people aged 2-49 years.

The U.S. Food and Drug Administration said the vaccine FluMist Quadrivalent, which is manufactured by AstraZeneca's MedImmune unit, is the first vaccine that contain four strains of the influenza virus -- two strains each of influenza A and B.

'A vaccine containing the four virus strains most likely to spread and cause illness during the influenza season offers an additional option to aid in influenza prevention efforts,' said Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research.

(Reporting by Anand Basu in Bangalore; Editing by Maju Samuel) Keywords: ASTRAZENECA/

(; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging:

Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

Related Shares:

Next Article: Florence Welch eclipses Adele at NME music awards

Back to Finance News

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.